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Introduction
Glucose-dependent insulinotropic polypeptide (GIP) is a gluco-regulatory hormone released from K-cells in response to feeding [1] . Despite initial characterisation based on its ability to inhibit gastric acid secretion, GIP, together with its sister hormone, glucagon-like peptide-1 (GLP-1), are now widely recognised as incretin hormones [2] . GIP and GLP-1 account for the total insulinotropic arm of the enteroinsular axis following meal ingestion, thereby reducing postprandial hyperglycaemia [3] . In contrast to currently used non-endogenous drugs, both GIP and GLP-1 elicit their potent insulinotropic actions in a glucose-dependent manner and as such avoid unwanted hypoglycaemic episodes. While GLP-1 based therapies, for example, exenatide, have now reached the market and are currently being prescribed to type 2 diabetic patients, the progression of GIP-based molecules has been somewhat hindered due to several fundamental limitations [4] .
Firstly, insensitivity of the beta-cell to the insulin-releasing actions of GIP in type 2 diabetes has been noted [5, 6] . However, it has emerged that rather than representing a GIP specific defect, this is a readily reversible phenomenon that can be rectified by improved diabetes control using other glucose-lowering drugs [7, 8] . Thus combination therapy or use of modified GIP analogues can be expected to overcome any beta-cell insensitivity. Indeed the insulin-releasing and anti-diabetic potential of several amino-terminally modified GIP analogues have been demonstrated both in animal models and in preliminary studies in patients with type 2 diabetes [9] . Secondly, the pharmacokinetic profile of the native GIP hormone is severely compromised through rapid proteolytic degradation with the enzyme dipeptidylpeptidase-IV (DPP-IV; EC 3.4.14.5) generating the inactive major degradation product GIP(3-42) [10] . Thirdly, GIP and its associated metabolites are quickly eliminated and cleared from the body primarily via the kidney [11] .
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Furthermore, present appreciation of the role of circulating GIP in clinical diabetes and particularly fat deposition is far from complete [4] .
These intrinsic limitations can be overcome through two different approaches including the application of specific DPP-IV inhibitors or the development of structurally modified GIP molecules which are resistant to the actions of DPP-IV [12] . Indeed, a range of structurally modified analogues of GIP have been developed, several of which have improved antihyperglycaemic and insulinotropic properties [4] . Recently, we have shown that GIP conjugated at the C-terminus with a mini-polyethylene glycol residue exhibited prolonged and enhanced biological actions in vivo [13] . However, another approach to avoid rapid renal filtration and clearance from the body is fatty acid derivatisation. Studies in our laboratory have shown that conjugating a C-16 fatty acid to the epsilon side-chain of Lys at position 37 resulted in significant benefits in both glucose-lowering and insulin-releasing actions [14] [15] [16] [17] [18] . Fatty acid derivatisation prolongs the biological half-life of GIP by masking the DPP-IV cleavage sight, but also facilitates binding to serum proteins thus reducing renal clearance [15, 16] . Indeed, this approach has been employed in the development of several GLP-1 based therapies, for example, NN2211, which has been shown to elicit a prolonged pharmacodynamic profile (half-life >12h) making it suitable for once-daily subcutaneous administration [19] . However, unlike GIP-based mimetics, prolonged administration of NN2211 and GLP-1 mimetics in general leads to gastrointestinal side-effects such as nausea due to a prolonged inhibitory effect on gastric emptying [9] .
To date, only the biological efficacy of C-16 fatty acid derivatised GIP analogues have been reported [14] [15] [16] [17] [18] . Therefore, in the present study we characterised the effects of a range of fatty acid chain lengths (C-14, C-16 and C-18) with or without N-terminal acetylation on metabolic 51 stability and biological actions. Stability of GIP analogues to DPP-IV degradation, as well as in vitro cAMP production and insulin secretion were examined. Furthermore, acute and prolonged actions of selected analogues were assessed in ob/ob mice, a commonly employed animal model of type 2 diabetes displaying both beta-cell dysfunction and insulin resistance.
Materials and methods

2.1
Synthesis, purification and characterisation of GIP peptides GIP peptides (see Table 1 ) were sequentially synthesised on an Applied BioSystems automated peptide synthesiser (ABI 432A Peptide Synthesiser; Warrington, Cheshire, UK) with a preloaded Fmoc-Gln(Trt)-Wang resin (typical loading 0.2-1.0 mmol/g; Sigma-Aldrich, Gillingham, Dorset, UK) using standard solid-phase Fmoc peptide chemistry [21] . Synthetic peptides were purified by semi-preparative HPLC followed by analytical HPLC and characterised using matrix-assisted laser desorption ionisation-time of flight (MALDI-TOF) mass spectrometry as described previously [16] .
Degradation of GIP peptides by DPP-IV
GIP peptides were incubated at 37°C in 50 mM triethanolamine-HCl (pH 7.8) with purified porcine dipeptidylpeptidase-IV (5 mU; Sigma-Aldrich, UK) for 0, 2, 4, 8 and 24 h (no albumin was present in the incubation buffer). Enzymatic reactions were terminated by addition of 15 μl of 10% (v/v) TFA/water. Reaction products were applied to a Vydac C-4 column (4.6 x 250mm;
The Separations Group, Hesparia, California, USA) and intact peptide separated from the major degradation fragment GIP . Absorption was monitored at 206 nm using a SpectraSystem UV2000 detector (Thermoquest Ltd, Manchester, UK) and HPLC peak area data were used to calculate percentage intact peptide remaining at time points indicated during the incubation. 61
In vitro cAMP production and insulin secretion
The effects of GIP peptides on the stimulation of cAMP production and insulin secretion were measured using clonal pancreatic BRIN-BD11 cells as described previously [22] . For cAMP studies, BRIN-BD11 cells were seeded (100,000 cells per well) into 96-well plates (Nunc, Roskilde, Denmark) and washed with HBS buffer before being incubated with various concentrations of GIP peptides in the presence of 1 mM IBMX (Sigma-Aldrich, UK) for 20 min at 37°C. After incubation, medium was removed and the cells lysed prior to measurement of cAMP using an HTS Immunoassay Kit (Millipore, Watford, UK). For insulin-release studies, BRIN-BD11 cells were seeded (100,000 cells per well) into 24-well plates (Nunc, Roskilde, Denmark) and allowed to attach overnight at 37°C. Following a 40 min pre-incubation (1.1 mM glucose; 37 o C), cells were incubated (20 min; 37°C) in the presence of 5.6 mM glucose with a range of peptide concentrations (estimated albumin concentration 76.5 μM). After 20 min incubation, buffer was removed from each well and aliquots (200 μl) stored at -20°C prior to measurement of insulin using radioimmunoassay.
Acute and persistent effects of GIP peptides on glucose-lowering and insulin release in vivo
Obese diabetic (ob/ob) mice and lean littermates from the Aston colony at 20-22 weeks of age were used to assess the in vivo biological properties of GIP peptides. The genetic background and characteristics of the colony used have been described in detail elsewhere [20] . Animals were age-matched, divided into groups and housed in an air-conditioned room at 22 ± 2°C with a 12 h light / 12 h dark cycle. Animals had free access to drinking water and normal laboratory chow (Trouw Nutrition, Cheshire, UK). All animal experiments were performed in accordance with the M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 was assayed by an automated glucose oxidase procedure [23] using a Beckman Glucose Analyser II (Beckman Instruments, Galway, Ireland). Plasma and pancreatic insulin was assayed by a modified dextran-coated charcoal radioimmunoassay as described previously [24] . Plasma triglyceride levels were measured using a Hitachi Automatic Analyser 912 (Boehringer Mannheim, Germany) as per manufacturer instructions.
Statistical analysis
Results are expressed as mean ± SEM and data compared using the unpaired Student's t-test.
Where appropriate, data were compared using repeated measures ANOVA or one-way ANOVA, followed by the Student-Newman-Keuls post-hoc test. Incremental area under the curve (AUC) analyses for plasma glucose and insulin were calculated using GraphPad Prism version 3.02.
Groups of data were considered to be significantly different if p < 0.05.
Results
3.1.
Structural characterisation and DPP-IV stability of GIP peptides.
Following solid-phase peptide synthesis and HPLC purification, the molecular mass of each peptide was determined using MALDI-TOF MS ( 
3.2.
In vitro cAMP production and insulin secretion Native GIP stimulated intracellular cAMP production in a concentration-dependent manner in BRIN-BD11 cells with an EC 50 value of 0.70 nM. GIP analogues followed a similar pattern of concentration-dependent stimulation of cAMP production but exhibited improved EC 50 values (0.07 to 0.27 nM; Table 1 ). Consistent with effects on cAMP production, native GIP dose- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   11 3.5. Effects of daily administration of N-AcGIP, GIP(Lys 37 MYR) and N-AcGIP(Lys 37 MYR) on bodyweight, food intake, non-fasting glucose and insulin concentrations in ob/ob mice Daily administration of N-AcGIP, GIP(Lys 37 MYR) and N-AcGIP(Lys 37 MYR) for 24 days had no effect on body weight and food intake compared to saline-treated controls ( Fig. 6A and 6B ). Nonfasting plasma glucose concentrations were significantly lower in GIP(Lys 37 MYR) (1. Table 2 , plasma glucose AUC values were not significantly changed in any of the treatment groups following administration of exogenous insulin. Similarly, pancreatic insulin content and circulating plasma triglyceride concentrations were not significantly different between treated and control groups ( Table 2 ).
Discussion
Renewed interest into the potential use of incretin hormones as antidiabetic therapies has emerged in recent years [4] . The glucose-dependent insulin secretion induced by GLP-1 and GIP offers benefits over currently used single action, non-endogenous drugs that stimulate insulin secretion at any glucose concentration. Lack of effect of GIP on gastric emptying offers a potential advantage compared with therapies based on GLP-1 [9] . However, circulating GIP is rapidly hydrolysed by the ubiquitous enzyme DPP-IV and efficiently cleared from the body through renal filtration [11] . The potential of C-16 fatty acid (PAL) conjugated GIP analogues has been explored recently with N-AcGIP(Lys 37 PAL) appearing to be the most promising analogue [15, 16] . The present study examined further the effect of fatty acid chain length, with or without N-terminal acetylation, on biological efficacy through assessing in vitro and in vivo antihyperglycaemic and insulinotropic properties. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 13 intact throughout the entire 24 h incubation (half-lives >24 h). While the conditions used for the DPP-IV assay in the present study were not able to discriminate t 1/2 between analogues, more detailed examination of SAR would be of interest in future studies. However, despite the probability of peptide adsorption during the longer incubation periods, this confirms in vitro DPP-IV resistance of each GIP analogue tested. It therefore appears that N-terminal acetylation and the addition of C14-C18 fatty acid residue close to the C-terminal region inhibits the action of DPP-IV, perhaps by disrupting the GIP hydro-affinity for the enzyme, as reported previously [16] . Interestingly, C14-C18 acylation without additional N-terminal acetylation also resulted in stable GIP analogues most likely due to steric hindrance.
Broadly similar to previous studies, native GIP concentration-dependently stimulated cAMP production with an EC 50 value of 0.70 nM [16] . Likewise, GIP analogues stimulated cAMP production in a concentration-dependent manner. However, analogues demonstrated up to a 10fold reduction in EC 50 value relative to GIP. This suggests enhanced potency at the GIP receptor, and is indicative of preserved receptor affinity with improved activation of the adenylate cyclase transduction pathway. This increased potency is corroborated by GIP analogues significantly inducing concentration-dependant stepwise increases in insulin secretion from BRIN-BD11 cells.
At the highest concentrations, GIP analogues evoked a notable improvement in insulin secretion which quite likely reflects both increased potency and enhanced biological half-life [16] . Since no significant degradation of GIP occurred during these in vitro incubations, these data suggest that the combination of increased DPP-IV resistance and improved biological potency at the cellular level should provide analogues with greatly enhanced activity in vivo.
To assess the antihyperglycaemic and insulinotropic effects of GIP analogues in vivo, we employed the ob/ob mouse model from the Aston colony [20] . On this genetic background, ob/ob M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 14 mice present with hyperphagia, marked obesity, moderate hyperglycaemia and severe hyperinsulinaemia representing a very robust model of type 2 diabetes and obesity. As in previous studies, native GIP had no significant effect on plasma glucose or the insulin response following an intraperitoneal glucose load [16, 17] 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 15 AcGIP(Lys 37 MYR) suggests a much more extended plasma half-life, reflecting an enhanced ability of this shorter C-14 chain to structurally orientate and bind more strongly to serum proteins preventing kidney filtration [11] . The development of a specific assay to assess plasma levels of these fatty acid GIP analogues would be necessary to provide more precise details of these kinetics.
Results of these acute in vivo studies provided a strong basis for the subsequent 24 day study.
Daily intraperitoneal injection of N-AcGIP, GIP(Lys 37 MYR) and N-AcGIP(Lys 37 MYR) over this time had no apparent adverse or toxic effects. Bodyweight and food intake were similar to salinetreated controls confirming previous findings [15] . Importantly, GIP(Lys 37 MYR) and N-AcGIP(Lys 37 MYR), and to a lesser effect, N-AcGIP, significantly reduced plasma glucose levels from day 20 of the study, accompanied by significantly elevated plasma insulin levels. Glucose tolerance was markedly improved in animals treated with GIP(Lys 37 MYR) and N-AcGIP(Lys 37 MYR) and this was accompanied by significantly increased plasma insulin concentrations. This confirms the long-acting insulinotropic effects of these analogues and their ability to overcome the severe beta-cell defect in this model. Improvement in glucose homeostasis was independent of any change in insulin sensitivity which is in agreement with previous findings [14 -18] . There were no observed changes in pancreatic insulin content or plasma triglyceride levels although a more prolonged treatment period may be necessary to see improvements in these parameters.
In conclusion, this study demonstrated that fatty acid derivatisation at position Lys 37 , with or without N-terminal acetylation confers DPP-IV resistance and improved biological efficacy during in vitro and acute in vivo studies. Furthermore, derivatisation with a C-14 fatty acid offered a more protracted and markedly improved biological function over C-16 and C-18 fatty M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 16 acid counterparts. These data represent an important step in the progression of fatty acid derivatised GIP analogues as a potential therapy for type 2 diabetes. Further studies are required to answer whether or not these analogues will be useful in human diabetes treatment.
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Legends to Figures
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Peptide treatment Insulin sensitivity (glucose AUC)
Insulin content (ng/g tissue)
Triglycerides (ng/dl)
A c c e p t e d M a n u s c r i p t 
